Share this article

Orthofix Medical has launched a synthetic bioactive bone graft solution, Opus BA, for cervical and lumbar spine fusion procedures.

With the full market launch of the solution, the company has expanded its synthetic bone growth offerings.

Acting as a scaffold, Opus BA allows bone to grow across the surface and is reabsorbed and replaced with natural bone while healing.

The solution is available in putty and strip formulations and can be used to fill bone voids or gaps in the skeletal system.

The company stated that Opus BA is hydrated with autogenous bone marrow or autograft with saline.

It is claimed to be moldable and useful for versatile applications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Orthofix global spine president Kevin Kenny said: “We recognise that each bone substitute has its own unique advantages and surgeons have different preferences when evaluating the use of autologous, allogeneic or synthetic bone graft materials for their patients.

“The addition of Opus BA is another example of our commitment to providing surgeons with a wide range of solutions, so they can select the best bone substitute for each patient.”

The osteoconductive matrix of Opus BA is created using a specific mix of components, including bioactive glass, carbonate apatite bone mineral and Type 1 Collagen carrier.

These materials have the ability to stimulate the formation, growth and resorption of bone.

Orthofix currently markets and distributes Collage osteoconductive scaffold, FiberFuse Advanced moldable allograft, and Trinity Elite and Trinity Evolution allografts with viable cells.

The company’s portfolio also includes AlloQuent structural allograft, Opus Mg Set bone void filler, the O-Genesis graft delivery system, the FiberFuse Strip preformed allograft and VersaShield amniotic membrane.